| Description |
With increasing resource pressure, drug developers need to make more effective and informed go/no-go decisions as early as possible in the drug development process. This allows the best compounds to move ahead with adequate resource support. By doing more of the right experiments, earlier in the pre-clinical discovery and development process, drug developers will face fewer surprises as drugs move into the more expensive later stages of the development process. Biomarkers, FDG-PET Imaging, Gene Expression, Metabolic Screening, Protein Tomography and other advanced tools are increasingly being used for early confirmation of a drug development candidate’s ability to reach a target, confirm bioavailability and impact on a target or pathway, to enable an earlier, more effective, decision making processes. Leading drug discovery and development companies are increasingly reorganizing their drug development process and programs to take advantage of these new tools and techniques to improve drug development pipeline productivity and focus resources on the most promising candidates.
www.healthtech.com
|
|
